Half-dose ticagrelor versus clopidogrel dual antiplatelet therapy in flow diverter-treated intracranial aneurysms: analysis of platelet reactivity and perioperative safety outcomes

This study demonstrates that half-dose ticagrelor DAPT achieves significantly lower platelet reactivity (ADPi-MPA) compared to standard-dose clopidogrel, with no statistically significant differences in ischemic or hemorrhagic complication rates observed among FD-treated IA patients. Importantly, the half-dose regimen shows consistent performance across different FD devices (including PED Flex Shield) without compromising perioperative safety.